These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
409 related articles for article (PubMed ID: 24302750)
1. Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. Else T; Williams AR; Sabolch A; Jolly S; Miller BS; Hammer GD J Clin Endocrinol Metab; 2014 Feb; 99(2):455-61. PubMed ID: 24302750 [TBL] [Abstract][Full Text] [Related]
2. Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study. Weigand I; Altieri B; Lacombe AMF; Basile V; Kircher S; Landwehr LS; Schreiner J; Zerbini MCN; Ronchi CL; Megerle F; Berruti A; Canu L; Volante M; Paiva I; Della Casa S; Sbiera S; Fassnacht M; Fragoso MCBV; Terzolo M; Kroiss M J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32449514 [TBL] [Abstract][Full Text] [Related]
3. Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. Berruti A; Grisanti S; Pulzer A; Claps M; Daffara F; Loli P; Mannelli M; Boscaro M; Arvat E; Tiberio G; Hahner S; Zaggia B; Porpiglia F; Volante M; Fassnacht M; Terzolo M J Clin Endocrinol Metab; 2017 Apr; 102(4):1358-1365. PubMed ID: 28324035 [TBL] [Abstract][Full Text] [Related]
4. Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group. Postlewait LM; Ethun CG; Tran TB; Prescott JD; Pawlik TM; Wang TS; Glenn J; Hatzaras I; Shenoy R; Phay JE; Keplinger K; Fields RC; Jin LX; Weber SM; Salem A; Sicklick JK; Gad S; Yopp AC; Mansour JC; Duh QY; Seiser N; Solorzano CC; Kiernan CM; Votanopoulos KI; Levine EA; Staley CA; Poultsides GA; Maithel SK J Am Coll Surg; 2016 Apr; 222(4):480-90. PubMed ID: 26775162 [TBL] [Abstract][Full Text] [Related]
5. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. Icard P; Goudet P; Charpenay C; Andreassian B; Carnaille B; Chapuis Y; Cougard P; Henry JF; Proye C World J Surg; 2001 Jul; 25(7):891-7. PubMed ID: 11572030 [TBL] [Abstract][Full Text] [Related]
6. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. Fassnacht M; Johanssen S; Fenske W; Weismann D; Agha A; Beuschlein F; Führer D; Jurowich C; Quinkler M; Petersenn S; Spahn M; Hahner S; Allolio B; J Clin Endocrinol Metab; 2010 Nov; 95(11):4925-32. PubMed ID: 20668036 [TBL] [Abstract][Full Text] [Related]
7. A clinical study and treatment results of adrenocortical carcinoma patients presented in Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore. Khan MS; Ali A; Tariq I; Khan MA; Bakar MA; Anwar AW J Pak Med Assoc; 2019 May; 69(5):717-719. PubMed ID: 31105294 [TBL] [Abstract][Full Text] [Related]
8. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884 [TBL] [Abstract][Full Text] [Related]
9. Diagnosis, treatment and outcome of adrenocortical cancer. Mihai R Br J Surg; 2015 Mar; 102(4):291-306. PubMed ID: 25689291 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. Fassnacht M; Hahner S; Polat B; Koschker AC; Kenn W; Flentje M; Allolio B J Clin Endocrinol Metab; 2006 Nov; 91(11):4501-4. PubMed ID: 16895957 [TBL] [Abstract][Full Text] [Related]
15. National Treatment Practice for Adrenocortical Carcinoma: Have They Changed and Have We Made Any Progress? Tierney JF; Chivukula SV; Poirier J; Pappas SG; Schadde E; Hertl M; Kebebew E; Keutgen X J Clin Endocrinol Metab; 2019 Dec; 104(12):5948-5956. PubMed ID: 31361313 [TBL] [Abstract][Full Text] [Related]
16. Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence. Calabrese A; Basile V; Puglisi S; Perotti P; Pia A; Saba L; Berchialla P; Porpiglia F; Veltri A; Volante M; Reimondo G; Berruti A; Terzolo M Eur J Endocrinol; 2019 Jun; 180(6):387-396. PubMed ID: 30991359 [TBL] [Abstract][Full Text] [Related]
17. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. Michalkiewicz E; Sandrini R; Figueiredo B; Miranda EC; Caran E; Oliveira-Filho AG; Marques R; Pianovski MA; Lacerda L; Cristofani LM; Jenkins J; Rodriguez-Galindo C; Ribeiro RC J Clin Oncol; 2004 Mar; 22(5):838-45. PubMed ID: 14990639 [TBL] [Abstract][Full Text] [Related]
18. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. Grubbs EG; Callender GG; Xing Y; Perrier ND; Evans DB; Phan AT; Lee JE Ann Surg Oncol; 2010 Jan; 17(1):263-70. PubMed ID: 19851811 [TBL] [Abstract][Full Text] [Related]
19. How is adrenocortical cancer being managed in the UK? Aspinall SR; Imisairi AH; Bliss RD; Scott-Coombes D; Harrison BJ; Lennard TW Ann R Coll Surg Engl; 2009 Sep; 91(6):489-93. PubMed ID: 19558758 [TBL] [Abstract][Full Text] [Related]
20. Adrenocortical carcinoma: clinicopathological features, prognostic factors and outcome. Keskin S; Taş F; Vatansever S Urol Int; 2013; 90(4):435-8. PubMed ID: 23343838 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]